Le Lézard
Classified in: Health
Subjects: NPT, PER

S. Louis Bridges, Jr., MD, PhD, Named Physician-in-Chief and Chair of Rheumatology at Hospital for Special Surgery


NEW YORK, Feb. 27, 2020 /PRNewswire/ -- Hospital for Special Surgery (HSS) today announced the appointment of S. Louis Bridges, Jr., MD, PhD, as the new Physician-in-Chief and Chair of the Division of Rheumatology, effective September 1, 2020.  Dr. Bridges succeeds Mary K. Crow, MD, who will become Physician-In-Chief Emeritus.

S. Louis Bridges, Jr., MD, PhD, Named New Physician-in-Chief and Chair of the Division of Rheumatology at HSS, effective September 1.

"Dr. Bridges is a distinguished and well-respected physician-scientist whose work has led to great improvements in patient care," said Bryan Kelly, MD, Surgeon-in-Chief and Medical Director at HSS. "His experience and expertise will only enhance our commitment to delivering high-quality and high-value healthcare."

Dr. Bridges, a rheumatologist, is the director of the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB), where he serves as the Anna Lois Waters Endowed Chair of the Division of Clinical Immunology and Rheumatology. He is also the Director of UAB's Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center.

He earned his bachelor's degree from the University of Notre Dame, his medical degree from Louisiana State University School of Medicine and his PhD degree in microbiology from UAB. He completed his residency and fellowship at the University of Texas Medical Branch in internal medicine, where he also served as Chief Medical Resident. He has been continuously funded by National Institutes of Health grants and is focused largely on rheumatoid arthritis susceptibility and treatment response. Dr. Bridges has authored more than 140 manuscripts and 20 book chapters and has served as editor of three editions of the text Vasculitis, published by Oxford University Press. In January 2020, Dr. Bridges was appointed president of the Rheumatology Research Foundation and member of the Executive Committee of the American College of Rheumatology.

Additionally, he is a former co-editor of Arthritis & Rheumatology and former chair of the NIH Arthritis, Musculoskeletal, and Skin Study Section. In addition to membership on several American College of Rheumatology committees, he previously served as chair of the ACR Committee on Research and as a member of the Rheumatology Research Foundation's Scientific Advisory Council.

"I am excited and humbled by the privilege of leading the renowned HSS Department of Medicine to further advance the science and practice of Rheumatology and related specialties," said Dr. Bridges.  "Together with esteemed colleagues in Orthopedics, there is no greater opportunity to impact musculoskeletal health worldwide."

Dr. Crow will remain at HSS continuing her work as the Benjamin M. Rosen Chair in Immunology and Inflammation Research and the Joseph P. Routh Professor of Rheumatic Diseases Medicine.

"Dr. Crow is an exceptional international leader, and her dedication to improving the lives of patients with autoimmune conditions has led to incredible scientific breakthroughs," said Dr. Kelly. "We're looking forward to her continued success at HSS."  

"The advancement of patient care practices at HSS is demonstrated through our commitment to recruiting outstanding physician leaders in our clinical specialties, such as Dr. Bridges," said Louis A. Shapiro, president and CEO at HSS. "Dr. Bridges has made significant contributions to the field of rheumatology. He approaches complex cases with dedication and compassion, and is an advocate for populations disproportionately affected by rheumatic diseases. We are proud to welcome him to HSS."

About HSS

HSS is the world's leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the tenth consecutive year), No. 3 in rheumatology by U.S. News & World Report (2019-2020), and named a leader in pediatric orthopedics by U.S. News & World Report "Best Children's Hospitals" list (2019-2020). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In addition, HSS will be opening a new facility in Florida in early 2020. In 2018, HSS provided care to 139,000 patients and performed more than 32,000 surgical procedures, and people from all 50 U.S. states and 80 countries travelled to receive care at HSS. There were more than 37,000 pediatric visits to the HSS Lerner Children's Pavilion for treatment by a team of interdisciplinary experts. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is the world's leading provider of education on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

SOURCE Hospital for Special Surgery


These press releases may also interest you

at 08:05
Merck , known as MSD outside the United States and Canada, announced today a commitment to strengthen health systems affected by the COVID-19 pandemic. Through Merck for Mothers, the company's global initiative to help end preventable maternal...

at 08:05
A new startup, i2O Therapeutics, has launched to commercialize innovations developed at Harvard University that may one day enable patients and clinicians to give up syringes in favor of pills. Using ionic liquid technologies developed in the lab...

at 08:05
X4 Pharmaceuticals, Inc. , a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present and conduct one-on-one meetings during the...

at 08:05
i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund. Founded by...

at 08:05
Tango Therapeutics, a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of an oversubscribed Series B financing of $60 million led by Boxer Capital of the...

at 08:05
Riptide Bioscience, Inc., today announced that Dame Carol M. Black, FRCP, MACP, FMedSci, Foreign Associate Member of the Institute of Medicine USA, renowned clinician/scientist and eminent expert in systemic sclerosis, has joined the company's...



News published on 27 february 2020 at 08:02 and distributed by: